Cargando…
Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report
Patient: Male, 37-year-old Final Diagnosis: Immune-mediated myocarditis • pulmonary vasculitis • myositis • thrombocytopenia Symptoms: Episode of hemoptysis with blood less than 100 ml • one-day history of sudden onset severe shortness of breath associated with orthopnea, dry cough and excessive swe...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865877/ https://www.ncbi.nlm.nih.gov/pubmed/35173141 http://dx.doi.org/10.12659/AJCR.934399 |
_version_ | 1784655713087258624 |
---|---|
author | Al-Rasbi, Sara Al-Mqbali, Juhaina Salim Al-Farsi, Rajaa Shukaili, Moza Ali Al Al-Riyami, Maryam H. Falahi, Zubaida Al Farhan, Hatem Al Al Alawi, Abdullah M. |
author_facet | Al-Rasbi, Sara Al-Mqbali, Juhaina Salim Al-Farsi, Rajaa Shukaili, Moza Ali Al Al-Riyami, Maryam H. Falahi, Zubaida Al Farhan, Hatem Al Al Alawi, Abdullah M. |
author_sort | Al-Rasbi, Sara |
collection | PubMed |
description | Patient: Male, 37-year-old Final Diagnosis: Immune-mediated myocarditis • pulmonary vasculitis • myositis • thrombocytopenia Symptoms: Episode of hemoptysis with blood less than 100 ml • one-day history of sudden onset severe shortness of breath associated with orthopnea, dry cough and excessive sweating • reducing sensation to fine touch and temperature at the entire left upper limb • three-days history of back pain Medication: — Clinical Procedure: — Specialty: General and Internal Medicine OBJECTIVE: Unusual clinical course BACKGROUND: The COVID-19 pandemic is a current global crisis, and there are hundreds of millions of individuals being vaccinated worldwide. At present, there have been few reports of COVID-19 vaccine-induced autoimmune processes manifested as myositis, thrombocytopenia, and myocarditis. CASE REPORT: A 37-year-old man presented to the Emergency Department (ED) with a 3-day history of back pain and a 1-day history of left upper limb swelling with paresthesia and shortness of breath, 12-days after receiving the first dose of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine. He was diagnosed with severe myositis complicated with rhabdomyolysis and non-oliguric acute kidney injury, thrombocytopenia, myocarditis with pulmonary edema, and pulmonary hemorrhage. Screens for potential toxic, infectious, paraneoplastic, and autoimmune disorders were unremarkable. The patient was treated with a 5-day course of intravenous methylprednisolone and intravenous immunoglobulin, with a good response. He was hospitalized for 16 days and discharged home on a tapering dose of oral prednisolone for 6 weeks. CONCLUSIONS: The case describes a possible link between Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine and immune-mediated myocarditis, pulmonary vasculitis, myositis, and thrombocytopenia. However, further data are required to confirm such an association. |
format | Online Article Text |
id | pubmed-8865877 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | International Scientific Literature, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88658772022-03-17 Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report Al-Rasbi, Sara Al-Mqbali, Juhaina Salim Al-Farsi, Rajaa Shukaili, Moza Ali Al Al-Riyami, Maryam H. Falahi, Zubaida Al Farhan, Hatem Al Al Alawi, Abdullah M. Am J Case Rep Articles Patient: Male, 37-year-old Final Diagnosis: Immune-mediated myocarditis • pulmonary vasculitis • myositis • thrombocytopenia Symptoms: Episode of hemoptysis with blood less than 100 ml • one-day history of sudden onset severe shortness of breath associated with orthopnea, dry cough and excessive sweating • reducing sensation to fine touch and temperature at the entire left upper limb • three-days history of back pain Medication: — Clinical Procedure: — Specialty: General and Internal Medicine OBJECTIVE: Unusual clinical course BACKGROUND: The COVID-19 pandemic is a current global crisis, and there are hundreds of millions of individuals being vaccinated worldwide. At present, there have been few reports of COVID-19 vaccine-induced autoimmune processes manifested as myositis, thrombocytopenia, and myocarditis. CASE REPORT: A 37-year-old man presented to the Emergency Department (ED) with a 3-day history of back pain and a 1-day history of left upper limb swelling with paresthesia and shortness of breath, 12-days after receiving the first dose of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine. He was diagnosed with severe myositis complicated with rhabdomyolysis and non-oliguric acute kidney injury, thrombocytopenia, myocarditis with pulmonary edema, and pulmonary hemorrhage. Screens for potential toxic, infectious, paraneoplastic, and autoimmune disorders were unremarkable. The patient was treated with a 5-day course of intravenous methylprednisolone and intravenous immunoglobulin, with a good response. He was hospitalized for 16 days and discharged home on a tapering dose of oral prednisolone for 6 weeks. CONCLUSIONS: The case describes a possible link between Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine and immune-mediated myocarditis, pulmonary vasculitis, myositis, and thrombocytopenia. However, further data are required to confirm such an association. International Scientific Literature, Inc. 2022-02-17 /pmc/articles/PMC8865877/ /pubmed/35173141 http://dx.doi.org/10.12659/AJCR.934399 Text en © Am J Case Rep, 2022 https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) ) |
spellingShingle | Articles Al-Rasbi, Sara Al-Mqbali, Juhaina Salim Al-Farsi, Rajaa Shukaili, Moza Ali Al Al-Riyami, Maryam H. Falahi, Zubaida Al Farhan, Hatem Al Al Alawi, Abdullah M. Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report |
title | Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report |
title_full | Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report |
title_fullStr | Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report |
title_full_unstemmed | Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report |
title_short | Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report |
title_sort | myocarditis, pulmonary hemorrhage, and extensive myositis with rhabdomyolysis 12 days after first dose of pfizer-biontech bnt162b2 mrna covid-19 vaccine: a case report |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865877/ https://www.ncbi.nlm.nih.gov/pubmed/35173141 http://dx.doi.org/10.12659/AJCR.934399 |
work_keys_str_mv | AT alrasbisara myocarditispulmonaryhemorrhageandextensivemyositiswithrhabdomyolysis12daysafterfirstdoseofpfizerbiontechbnt162b2mrnacovid19vaccineacasereport AT almqbalijuhainasalim myocarditispulmonaryhemorrhageandextensivemyositiswithrhabdomyolysis12daysafterfirstdoseofpfizerbiontechbnt162b2mrnacovid19vaccineacasereport AT alfarsirajaa myocarditispulmonaryhemorrhageandextensivemyositiswithrhabdomyolysis12daysafterfirstdoseofpfizerbiontechbnt162b2mrnacovid19vaccineacasereport AT shukailimozaalial myocarditispulmonaryhemorrhageandextensivemyositiswithrhabdomyolysis12daysafterfirstdoseofpfizerbiontechbnt162b2mrnacovid19vaccineacasereport AT alriyamimaryamh myocarditispulmonaryhemorrhageandextensivemyositiswithrhabdomyolysis12daysafterfirstdoseofpfizerbiontechbnt162b2mrnacovid19vaccineacasereport AT falahizubaidaal myocarditispulmonaryhemorrhageandextensivemyositiswithrhabdomyolysis12daysafterfirstdoseofpfizerbiontechbnt162b2mrnacovid19vaccineacasereport AT farhanhatemal myocarditispulmonaryhemorrhageandextensivemyositiswithrhabdomyolysis12daysafterfirstdoseofpfizerbiontechbnt162b2mrnacovid19vaccineacasereport AT alalawiabdullahm myocarditispulmonaryhemorrhageandextensivemyositiswithrhabdomyolysis12daysafterfirstdoseofpfizerbiontechbnt162b2mrnacovid19vaccineacasereport |